focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

Tue, 02nd Apr 2024 11:50

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Oil majors and gold miners also soared in the FTSE 100 off the back of rising oil and bullion prices.

The FTSE 100 index was up 23.76 points, 0.3%, at 7,976.38. The FTSE 250 was down 58.37 points, 0.3%, at 19,826.36, and the AIM All-Share was up 0.40 of a point at 743.66.

The Cboe UK 100 was up 0.2% at 797.51, the Cboe UK 250 was down 0.7% at 17,220.34, and the Cboe Small Companies was up 0.2% at 14,590.74.

The UK manufacturing sector crossed the no-change mark into growth territory in March, according to the latest numbers from S&P Global.

The seasonally adjusted S&P Global UK manufacturing purchasing managers' index reading was 50.3 points in March, up from 47.5 in February and beating the earlier flash estimate of 49.9.

The latest figure was above the 50-point no-change mark, meaning the UK manufacturing sector returned to growth territory.

Pantheon Macroeconomics analyst Rob Wood commented: "The long downturn in manufacturing output is over according to the PMI...This isn't just a flash in the pan, with the forward-looking indications from the PMI suggesting growth will improve further.

"Expectations for growth in output over the next 12 months also improved to 75.9 in March from 73.5 in February, above their average level of 72.4 since this question was first asked in 2012 and the highest since April 2023."

UK house prices rose 1.6% in March compared to a year ago, according to the latest Nationwide survey and coming in below FXStreet-cited expectations of a 2.4% rise. In February, this rose by 1.2%.

On a monthly basis, prices fell 0.2% in March from February, compared to a 0.7% rise in February from January. The market expected a 0.3% rise.

"The UK housing market has been doing its best to bounce back, yet latest data from Nationwide would suggest it is still a slog to shift property," said AJ Bell analyst Russ Mould.

"House price growth was subdued in March as many people remain priced out of the market. We really need to see interest rate cuts to prompt a big drop in mortgage rates and improve affordability levels."

Market attention was otherwise dominated by the release of manufacturing PMI data, with more to come on Tuesday.

Growth in the US manufacturing sector continued in March but at a slower rate, final purchasing managers' index survey results from S&P Global confirmed on Monday, while the similar Institute for Supply Management survey showed a swing to growth from contraction.

The S&P Global US manufacturing PMI slipped to 51.9 points in March from 52.2 in February. This was below the flash result for March, released last month, which had shown an improvement to 52.5 points.

The score for last month was still above the neutral 50-point mark, and the expansion in production reached a 22-month-high.

The ISM PMI showed a more striking improvement last month, indicating a swing to expansion from contraction.

The ISM PMI for manufacturing reading was 50.3 points for March, compared to 47.8 for February and 49.1 for January. A less impressive rise to 48.4 points was expected for last month.

The readings came after data showed US inflation pressure eased ever-so-slightly in February to 2.8% on-year from 2.9% in January, according to the Federal Reserve's preferred indicator, the core personal consumption expenditures index. The data, released on Friday, was in line with consensus cited by FXStreet.

The core data excludes food and energy. The annual headline PCE index, which does not, picked up 2.5% in February, accelerating slightly from 2.4% in January. The February outcome was in line with consensus.

Stocks in New York were called lower. The Dow Jones Industrial Average was called down 0.3%, while the S&P 500 index and the Nasdaq Composite were both called down 0.2%.

Meanwhile, the eurozone's manufacturing sector sunk to a three-month low in March, numbers on Tuesday showed, though there were "signs of positive momentum building".

The latest Hamburg Commercial Bank manufacturing purchasing managers' index fell to 46.1 points in March, from 46.5 in February. The latest reading was a three-month low, but topped the flash estimate of 45.7 points.

Germany's manufacturing sector remained "firmly in contraction" in March, according to data from the Hamburg Commercial Bank on Tuesday.

The manufacturing purchasing managers' index for Germany registered 41.9 points in March, down from 42.5 points in February and further below the 50 point no-change mark.

A score of 50.0 separates expansion from decline.

In European equities on Tuesday, the CAC 40 in Paris was marginally down, while the DAX 40 in Frankfurt was down 0.2%.

The pound fell to USD1.2564 on Tuesday midday in London, compared to USD1.2640 at the equities close on Thursday last week. The euro stood lower at USD1.0741, against USD1.0803. Against the yen, the dollar was trading higher at JPY151.69 on Tuesday, compared to JPY151.29 late Thursday.

In London's FTSE 100, gold miners and oil majors were among the better large-cap performers.

Fresnillo and Anglo American traded 7.1% and 4.0% higher respectively, while Shell and BP rose 3.2% and 2.9% respectively.

Brent oil rose steeply to USD88.95 a barrel at midday in London on Tuesday from USD86.56 late Thursday last week. Gold rose to USD2,260.27 an ounce against USD2,221.01.

HSBC rose 1.0%, after it announced it sealed the sale of HSBC Bank Canada to Royal Bank of Canada.

The lender will book a USD4.9 billion "estimated gain on sale" in its first quarter, inclusive of the recycling of an estimated USD600 million in foreign currency translation reserve losses.

HSBC intends to declare a special dividend of USD0.21 per share in its first quarter earnings, subject to board approval and finalisation of results. This would be in addition to any proposed interim dividend and payable at the same time in June if approved.

AstraZeneca ticked down 0.1%.

The pharmaceutical firm said its biologics licence application for datapotamab deruxtecan was accepted by the US Food & Drug Administration for the treatment of specific forms of breast cancer.

AstraZeneca said the decision was based on the results of the Tropion-Breast01 phase 3 trial in which Dato-DXd "demonstrated a statistically significant and clinically meaningful improvement" in progression-free survival compared to chemotherapy and at least one systemic therapy.

The prescription drug user fee act date, the FDA action date for its regulatory decision, is during the first quarter of 2025.

Meanwhile, AstraZeneca's Voydeya has been approved in the US to treat extravascular haemolysis in adults suffering from rare blood disease paroxysmal nocturnal haemoglobinuria. The FDA approval comes off the back of positive results from the Alpha phase 3 trial.

In the FTSE 250, Hochschild Mining rose 2.6%, after the gold and silver miner sold its Crespo project in southern Peru for USD15 million to Kina Mining Peru.

Among London's small-caps, CMC Markets rose 3.9% to 226 pence, after RBC raised its price target for the online trading firm to 240p from 190p, rating the stock at 'outperform'.

On Wednesday last week, CMC Markets raised its full-year outlook after a positive fourth quarter.

In a trading update for the financial year ending March, the London-based online trading firm said it expects full-year net operating income to exceed the top end of the previously guided range of between GBP290 million and GBP310 million. This would be up from GBP288.4 million in financial 2023.

On AIM in London, Redx Pharma lost 59%, after it said intends to cancel its shares from trading on AIM in London, subject to shareholder approval.

The clinical-stage biotechnology company said the board unanimously concluded that it is in the best interests of the company to re-register as a private limited company, as it is "still liquidity constrained" on AIM.

A general meeting has been called for April 19 for Redx Pharma shareholders to vote on the cancellation resolution.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
13 Dec 2022 15:53

UK earnings, trading statements calendar - next 7 days

Wednesday 14 December 
Cohort PLCHalf Year Results
CyanConnode Holdings PLCHalf Year Results
Foresight Sustainable Forestry Co PLCFull Year Results
IntegraFin Holdings PLCFull Year Results
SThree PLCTrading Statement
Tui AGFull Year Results
Watches of Switzerland Group PLCHalf Year Results
Thursday 15 December 
Biffa PLCHalf Year Results
C4X Discovery Holdings PLCFull Year Results
Currys PLCHalf Year Results
Libertine Holdings PLCHalf Year Results
RWS Holdings PLCFull Year Results
Serco Group PLCTrading Statement
Friday 16 December 
Gore Street Energy Storage Fund PLCHalf Year Results
Hollywood Bowl Group PLCFull Year Results
Monday 19 December 
Thruvision Group PLCHalf Year Results
Tuesday 20 December 
Jersey Electricity PLCFull Year Results
Petrofac LtdTrading Statement
Redx Pharma PLCFull Year Results
  
Copyright 2022 Alliance News Ltd. All Rights Reserved.

Read more
11 Nov 2022 15:24

TRADING UPDATES: De La Rue defends chair; Resolute Mining fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
11 Oct 2022 14:51

TRADING UPDATES: Scirocco repays loan; Vp says rail strikes slow works

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Oct 2022 22:06

TRADING UPDATES: Blencowe Resources sees potential interest from China

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Aug 2022 13:58

Redx Pharma staff sell 1.5 million shares via accelerated bookbuild

(Alliance News) - Redx Pharma PLC on Friday confirmed that Chief Scientific Officer Richard Armer and other current and former employees have sold a total of 1.5 million shares at 59 pence each via an accelerated bookbuild.

Read more
3 Aug 2022 17:57

IN BRIEF: Redx Pharma employees to sell at least GBP605,120 in shares

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Chief Scientific Officer Richard Armer and other current and former employees look to sell 1.5 million shares at a minimum price of 59 pence each via an accelerated bookbuild, which is 11% discount to Tuesday's closing price of 66.50p.

Read more
27 Jun 2022 16:01

IN BRIEF: Redx Pharma reports "encouraging" fibrosis treatment data

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes encouraging preclinical data for the potential of its Porcupine and ROCK inhibitors to tackle cancer-associated fibrosis. Further data supported the ROCK inhibitor as a potential treatment for fibrostenotic Crohn's disease.

Read more
23 Jun 2022 11:29

IN BRIEF: Redx Pharma narrows half-year loss as pipeline progresses

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - In the half year ended March 31, pretax loss narrows to GBP9.7 million from GBP12.7 million year-on-year. Revenue multiplies to GBP8.4 million from GBP2.1million. Reports strong progress across its pipeline, especially its lead oncology asset RXC004 moving into phase II clinical trials, and its lead fibrosis asset, RXC007, reporting "encouraging" phase I safety data. Says its Rock inhibitor RXC008 has the potential to become a first-in-class treatment for fibrostenotic Crohn's disease, and is likely to be ready to enter the clinic by the end of next year.

Read more
16 Jun 2022 16:05

UK earnings, trading statements calendar - next 7 days

Friday 17 June 
Tesco PLCQ1 Results
Monday 20 June 
Associated British Foods PLCQ3 Results
SysGroup PLCFull Year Results
SThree PLCTrading Statement
Tuesday 21 June 
DS Smith PLCFull Year Results
Gear4Music PLCFull Year Results
Monks Investment Trust PLCFull Year Results
Record PLCFull Year Results
Safestore Holdings PLCHalf Year Results
Telecom Plus PLCFull Year Results
Wednesday 22 June 
Berkeley Group Holdings PLCFull Year Results
Liontrust Asset Management PLCFull Year Results
Micro Focus International PLCHalf Year Results
Thursday 23 June 
DeepVerge PLCFull Year Results
First Property Group PLCFull Year Results
Manolete Partners PLCFull Year Results
Naked Wines PLCFull Year Results
Oxford Metrics PLCHalf Year Results
Redx Pharma PLCHalf Year Results
Serco Group PLCTrading Statement
Volex PLCFull Year Results
XPS Pensions Group PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
15 Jun 2022 10:24

Redx Pharma rises on FDA clearance for solid tumour treatment JZP815

(Alliance News) - Redx Pharma PLC on Wednesday said the US Food & Drug Administration has cleared the investigational new drug application for JZP815, a pan-RAF inhibitor for the treatment of solid tumours and haematological malignancies.

Read more
19 May 2022 18:55

TRADING UPDATES: Knights tips revenue hike; Gym Group eyes growth

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 May 2022 19:37

IN BRIEF: Redx Pharma to raise GBP30 million to fund pipelines

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Proposes to raise GBP30 million through a placing to institutional investors of shares at a price of 59 pence each.

Read more
8 Apr 2022 19:41

IN BRIEF: Redx Pharma notes "encouraging" RXC004 data in cancer

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes "encouraging" preclincal data for RXC004 as a targeted therapy for Wnt-ligand driven cancer.

Read more
5 Apr 2022 21:39

TRADING UPDATES: Alpha FX restarts relationship; Atalaya resources up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 11:05

IN BRIEF: Redx Pharma to start new Crohn's disease study in late 2023

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Announces end of 2023 as start of phase 1 studies for its Crohn's disease clinical development candidate RXC008. The inhibitor is designed to act exclusively in the gastrointestinal tract at the site of fibrosis in Crohn's disease patients. Up to 50% of patients with Crohn's disease can develop significant fibrosis, the company says, citing a 2013 study published by the National Center for Biotechnology Information based in Bethesda, Maryland, United States.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.